The FDA recently approved Mirvaso (brimonidine, Galderma) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. The once-daily medication works quickly to reduce the redness of rosacea and lasts up to 12 hours. The approval was based on the results of two Phase III studies showing that adults who used Mirvaso demonstrated significantly greater improvement in the facial redness of rosacea than vehicle gel. Galderma says it expects Mirvaso to be available in pharmacies in September 2013.